Sichuan Hebang Biotechnology Co.Ltd(603077) 3 on the evening of March 14, the annual report of 2021 was released. The company achieved an operating revenue of 9.867 billion yuan in 2021, an increase of 87.56% year-on-year; The net profit attributable to the shareholders of the listed company was 3.023 billion yuan, a year-on-year increase of 728428%; The basic earnings per share is 0.36 yuan. The company plans to pay a cash dividend of 0.15 yuan (including tax) for every 10 shares.
According to the annual report, the price and sales volume of the company's main products increased in 2021. In addition, the company continued to improve management efficiency and staff quality, which ensured the company's high-quality operation, resulting in a significant increase in operating revenue.
Meanwhile, the company announced that it plans to spin off its holding subsidiary Wujun Guangneng to the main board of the Shanghai Stock Exchange. After the completion of this spin off, the equity structure of the company will not change and will still have a controlling stake in Wujun Guangneng. Through this spin off, the company will further focus its business, highlight its main business, focus on the development of traditional chemical and agricultural fields, and achieve excellence and strength; At the same time, it is conducive to the business development of the holding subsidiary Wujun Guangneng in the field of green energy.
